Frequency of rare BCR- ABL1 fusion transcripts in chronic myeloid leukemia patients.
Introduction The hallmark of chronic myeloid leukemia ( CML) is the presence of Philadelphia chromosome, its resultant fusion transcript ( BCR- ABL1), and fusion protein (p210). Alternate breakpoints in BCR (m-bcr, μ-bcr, and others) or ABL1 result in the expression of few rare fusion transcripts (e...
| Publicado en: | International Journal of Laboratory Hematology Vol. 39; no. 3; pp. 235 - 243 |
|---|---|
| Autores principales: | , , , , , , , , , , , |
| Formato: | research tables/charts Journal Article |
| Publicado: |
Wiley-Blackwell
Jun2017
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=123087331&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 123087331 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 17515521 47EA jtl: International Journal of Laboratory Hematology issn: 17515521 maglogo: Y pubinfo: dt: Jun2017 vid: 39 iid: 3 pid: 480 pub: Wiley-Blackwell place: Malden, Massachusetts artinfo: ui: 123087331 123087331 123087331 10.1111/ijlh.12616 123087331 ppf: 235 ppct: 8 formats: tig: atl: Frequency of rare BCR- ABL1 fusion transcripts in chronic myeloid leukemia patients. aug: au: Arun, A. K. Senthamizhselvi, A. Mani, S. Vinodhini, K. Janet, N. B. Lakshmi, K. M. Abraham, A. George, B. Srivastava, A. Srivastava, V. M. Mathews, V. Balasubramanian, P. affil: Department of Haematology, Christian Medical College, Vellore India sug: subj: Leukemia, Myeloid, Chronic Familial and Genetic Chromosome Disorders Oncogenes Chimerism RNA Human Gene Expression ab: Introduction The hallmark of chronic myeloid leukemia ( CML) is the presence of Philadelphia chromosome, its resultant fusion transcript ( BCR- ABL1), and fusion protein (p210). Alternate breakpoints in BCR (m-bcr, μ-bcr, and others) or ABL1 result in the expression of few rare fusion transcripts (e19a2, e1a2, e13a3, e14a3) and fusion proteins (p190, p200, p225) whose exact clinical significance remains to be determined. Methods Our study was designed to determine the type and frequency of BCR- ABL1 fusion transcripts in 1260 CML patients and to analyze the prognosis and treatment response in patients harboring rare BCR- ABL1 fusion transcripts. Results The frequency of various BCR- ABL1 fusion transcripts was as follows: e14a2 (60%), e13a2 (34.3%), e1a2 (1.2%), e1a2 + e13a2 (2.0%), e1a2 + e14a2 (1.8%), e19a2 (0.3%), and e14a3 (0.3%). CML patients with e1a2 transcripts had higher rates of disease progression, resistance, or suboptimal response to imatinib and failed to achieve major molecular response. Conclusion Characterization of the specific fusion transcript in CML patients is important owing to the difference in prognosis and response to therapy in addition to the conventional need for monitoring treatment response. CML patients with e1a2 transcripts have to be closely monitored due to the high incidence of disease progression and treatment resistance/failure. pubtype: Academic Journal doctype: research tables/charts Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|